Atara Biotherapeutics (LTS:0HIY) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0HIY Atara Biotherapeutics Inc LTS:0HIY
12 GF Score
Price $9.72
GF Value $0.47
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Atara Biotherapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Atara Biotherapeutics  (LTS:0HIY) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Atara Biotherapeutics Cyclically Adjusted PB Ratio Related Terms


Atara Biotherapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Atara Biotherapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atara Biotherapeutics Cyclically Adjusted PB Ratio Chart

Atara Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.86 0.69 0.12 0.12 0.26

Atara Biotherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.15 0.22 0.06 0.17

LTS:0HIY vs ICCC, FBIO, ALDX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Atara Biotherapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Cyclically Adjusted PB Ratio falls into.


LTS:0HIY
12GF Score
Atara Biotherapeutics Inc LTS:0HIY
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atara Biotherapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Atara Biotherapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Atara Biotherapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-3.918/333.9520*333.9520
=-3.918

Current CPI (Jun. 2026) = 333.9520.

Atara Biotherapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 234.208 241.428 323.965
201612 219.244 241.432 303.261
201703 200.225 243.801 274.263
201706 184.878 244.955 252.048
201709 168.287 246.819 227.696
201712 144.699 246.524 196.015
201803 250.145 249.554 334.743
201806 249.536 251.989 330.701
201809 220.755 252.439 292.037
201812 184.358 251.233 245.058
201903 6.132 254.202 8.056
201906 4.954 256.143 6.459
201909 5.883 256.759 7.652
201912 5.119 256.974 6.652
202003 4.289 258.115 5.549
202006 5.129 257.797 6.644
202009 4.583 260.280 5.880
202012 5.545 260.474 7.109
202103 4.746 264.877 5.984
202106 3.912 271.696 4.808
202109 3.509 274.310 4.272
202112 3.050 278.802 3.653
202203 2.402 287.504 2.790
202206 2.729 296.311 3.076
202209 1.972 296.808 2.219
202212 1.320 296.797 1.485
202303 0.673 301.836 0.745
202306 1.843 305.109 2.017
202309 -12.470 307.789 -13.530
202312 -23.305 306.746 -25.372
202403 -20.426 312.332 -21.840
202406 -22.608 314.175 -24.031
202409 -15.773 315.301 -16.706
202412 -16.604 315.605 -17.569
202503 -9.296 319.799 -9.707
202506 -5.022 322.561 -5.199
202509 -5.081 324.800 -5.224
202512 -5.257 324.054 -5.418
202603 -4.383 330.213 -4.433
202606 -3.918 333.952 -3.918

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Atara Biotherapeutics (LTS:0HIY) Overvalued in 2026?

Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued. The current stock price of $9.72 is trading 1969% above its estimated GF Value™ of $0.47. GuruFocus considers Atara Biotherapeutics to be Significantly Overvalued.

Key valuation signals for LTS:0HIY:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $0.47 vs. price of $9.72 (1969% above fair value)
  • GF Score™: 12/100 with 5 warning signs

No single metric tells the full story. See the LTS:0HIY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Atara Biotherapeutics Business Description

Other Exchanges ATRA:USAAT20:Germany
Address 1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
12GF Score

Get the complete analysis for LTS:0HIY

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.72
Price
$0.47
GF Value